434 related articles for article (PubMed ID: 29699889)
1. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.
Walden LM; Brandl EJ; Tiwari AK; Cheema S; Freeman N; Braganza N; Kennedy JL; Müller DJ
Psychiatry Res; 2019 Sep; 279():111-115. PubMed ID: 29699889
[TBL] [Abstract][Full Text] [Related]
2. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
Solomon HV; Cates KW; Li KJ
Psychiatry Res; 2019 Jan; 271():604-613. PubMed ID: 30554109
[TBL] [Abstract][Full Text] [Related]
3. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments.
Arranz MJ; Gonzalez-Rodriguez A; Perez-Blanco J; Penadés R; Gutierrez B; Ibañez L; Arias B; Brunet M; Cervilla J; Salazar J; Catalan R
Transl Psychiatry; 2019 Jul; 9(1):177. PubMed ID: 31346157
[TBL] [Abstract][Full Text] [Related]
4. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
5. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.
Austin-Zimmerman I; Wronska M; Wang B; Irizar H; Thygesen JH; Bhat A; Denaxas S; Fatemifar G; Finan C; Harju-Seppänen J; Giannakopoulou O; Kuchenbaecker K; Zartaloudi E; McQuillin A; Bramon E
Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828364
[TBL] [Abstract][Full Text] [Related]
6. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.
Bousman CA; Jaksa P; Pantelis C
Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243
[TBL] [Abstract][Full Text] [Related]
7. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
[TBL] [Abstract][Full Text] [Related]
8. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.
Müller DJ; Kekin I; Kao AC; Brandl EJ
Int Rev Psychiatry; 2013 Oct; 25(5):554-71. PubMed ID: 24151801
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.
Manworren RC; Jeffries L; Pantaleao A; Seip R; Zempsky WT; Ruaño G
Clin J Pain; 2016 Feb; 32(2):109-15. PubMed ID: 25803758
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.
Brandl EJ; Tiwari AK; Zhou X; Deluce J; Kennedy JL; Müller DJ; Richter MA
Pharmacogenomics J; 2014 Apr; 14(2):176-81. PubMed ID: 23545896
[TBL] [Abstract][Full Text] [Related]
11. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles.
Koopmans AB; Vinkers DJ; Gelan PJ; Hoek HW; van Harten PN
Pharmacogenomics; 2017 Jul; 18(10):1003-1012. PubMed ID: 28639468
[TBL] [Abstract][Full Text] [Related]
13. High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report.
Mian P; Somers M; Berg MT; Cahn W; Wilting I; Schaik RV
Pharmacogenomics; 2019 Jun; 20(8):567-570. PubMed ID: 31190622
[TBL] [Abstract][Full Text] [Related]
14. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
[TBL] [Abstract][Full Text] [Related]
15. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacogenetics in psychiatry: state of the art].
Müller DJ; Brandl EJ; Degenhardt F; Domschke K; Grabe H; Gruber O; Hebebrand J; Maier W; Menke A; Riemenschneider M; Rietschel M; Rujescu D; Schulze TG; Tebartz van Elst L; Tüscher O; Deckert J;
Nervenarzt; 2018 Mar; 89(3):290-299. PubMed ID: 29383410
[TBL] [Abstract][Full Text] [Related]
17. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
[TBL] [Abstract][Full Text] [Related]
18. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
19. Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study.
Calabrò M; Fabbri C; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; De Ronchi D; Serretti A; Crisafulli C
Eur Neuropsychopharmacol; 2022 Mar; 56():100-111. PubMed ID: 35152032
[TBL] [Abstract][Full Text] [Related]
20. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Practical issues related to medication selection.
Smoller JW
CNS Spectr; 2006 Mar; 11(3 Suppl 3):5-7. PubMed ID: 17760223
[No Abstract] [Full Text] [Related]
[Next] [New Search]
